All > Mantle Cell Lymphoma

Follow-Up for Mantle Cell Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mantle Cell Lymphoma+1 MoreFollow-Up - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial collects and tests samples to find personalized treatments for mantle cell lymphoma patients who have relapsed or are refractory to current treatment.

Eligible Conditions
  • Mantle Cell Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Cohort 2 (Co-trial cohort)
1
UCART19 follow-up
1
Decitabine and Cedazuridine

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Up to 1 year

Up to 1 year
Correlation of somatic mutations in mantle cell lymphoma with cell signaling dysregulated activity
Duration of response
Feasibility rate
Incidence of adverse events
Overall survival
Progression free survival
Response rate

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Cohort 2 (Co-trial cohort)
1
UCART19 follow-up
1
Decitabine and Cedazuridine

Trial Design

1 Treatment Group

Screening (biospecimen collection)
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Follow-Up · No Placebo Group · N/A

Screening (biospecimen collection)Experimental Group · 2 Interventions: Biospecimen Collection, Follow-Up · Intervention Types: Procedure, Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 1
~670

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,805 Previous Clinical Trials
1,790,514 Total Patients Enrolled
Luhua (Michael) WangPrincipal InvestigatorM.D. Anderson Cancer Center
14 Previous Clinical Trials
658 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a confirmed diagnosis of relapsed/refractory (R/R) MCL.
Patients must have bi-dimensional measurable disease as per Cheson criteria (bone marrow and or GI only involvement is acceptable).
You have a biopsy-accessible lesion and are willing to undergo biopsy.
You have lymphocytosis.
You have a performance status of 0-2.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top